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receiving a supply of drugs under the Australian government medication subsidy scheme; informed consent by each home's management to participate in the study; a record of hospitalisations, adverse events, and deaths.
Overall 3,230 residents participated in the study. Fifty-two nursing homes were enrolled from 116 invited homes (randomly selected from 134 eligible homes). A sample of 1,328 cross-sectional medication profiles was collected for 8 nursing home clusters (a total of 32 homes) in order to validate prescription claims data.
Study design
The study was a randomised controlled trial carried out in 52 nursing homes in Queensland and New South Wales. The 52 nursing homes participating in the study were matched on the basis of resident age, bed numbers and Resident Classification Instrument (RCI) into groups of 4 homes, yielding 13 clusters. A randomisation ratio of 1 (intervention) to 3 (control) was used. One home from each cluster was drawn from a hat and independently assigned to the intervention group (13 homes, 905 residents) and the remaining three homes to a control group (39 homes, 2,325 residents). Residents were followed for 12 months. All enrolled nursing homes completed the trial. Of the original 3,230 residents, 2,261 (70%) remained in the study nursing homes. Loss to follow-up was due to deaths or transfer to other homes.
Analysis of effectiveness
The basis for the analysis of the clinical study (intention to treat or treatment completers only) was not stated, but it seems that only treatment completers were considered.
The primary health outcomes assessed through nursing home records were: mortality rates and number of hospitalisations in the 12 months preceding the beginning of the study; number of residents who experienced adverse events in the 3 months prior to data collection; a composite RCI score; and resident survival from the start of intervention.
Survival curves were based on the Kaplan-Meier method. Survival hazard ratios were computed using Cox's proportional hazard models in order to compare survival in both intervention and control groups. Drug use and prescription claims for 1 year prior to and during the trial were analysed for the overall sample and for a cohort of 1,692 individual residents in study nursing homes for whom such records existed. These data were obtained from a government database. Several statistical tests were used to compare the groups.
Effectiveness results
No statistically significant changes were observed in annual mortality rates, frequency of hospitalisations, number of residents with adverse events or changes in the RCI score between the groups. Cumulative survival in the intervention group was higher than for the controls with a hazard ratio of 0.85 (95% CI: 0.75 -0.96, p<0.009), indicating that residents in the intervention groups were 15% more likely to survive longer than those in the control group. However, this results was not significant when the clustering effect was accounted for in the analysis, (p=0.13).
The baseline drug use was similar in both groups. However, in the trial period there was a decrease in the cumulative drug use in the intervention nursing home compared with control groups, which just failed to reach significance, (p=0.073). As earlier, when the clustering effect was not accounted for in the analysis, a drug use reduction of 14.8% was found in the intervention group compared to the control groups and the difference was statistically significant, (p<0.0005). Significant reductions in medication use were also apparent for some drug categories. On average, the intervention resulted in an overall shift in the drug use by one less drug per person.
